Injeq is participating in Congress of Joint European Neonatal Societies #jENS

Injeq is participating in Congress of Joint European Neonatal Societies #jENS. Our Chief Scientific Officer Dr. Harri Sievanen is presenting (poster 132).

Successful first attempt, less traumatic neonatal lumbar punctures

Meet Harri at poster session 7 – Epidemiology, on September 16th, 2021 at 13:30 – 14:30 for questions about bioimpedance guided lumbar punctures for neonates.

FDA grants breakthrough device designation for Injeq IQ-Tip® smart needle

Injeq is happy to announce that Injeq IQ-Tip device with its indications for use meet the criteria and have been […]
Read more »

Breakthrough Device designation granted by FDA

Injeq IQ-Tip system has been granted the Breakthrough Device designation by FDA! The FDA’s Breakthrough Devices Program is designed to […]
Read more »

Injeq grows – new distributor in Hong Kong

Injeq visited Hong Kong in May and met with local hospital management there. The interest towards Injeq IQ-Tip® system convinced […]
Read more »

Large multicenter trial of pediatric hemato-oncology patients sponsored by Injeq

A clinical investigation conducted in all five Finnish university hospitals and sponsored by Injeq has begun in May. A peer-reviewed […]
Read more »

Two more weeks to go!

There are two weeks left in Injeq’s share issue. Read the promising news and invest: Funding: Injeq Oyj (invesdor.com)   […]
Read more »

Injeq IQ-Tip®: Benefits for healthcare and society

Post-dural puncturel headache after lumbar puncture is a difficult post-procedure complication caused by cerebrospinal fluid seeping through the lumbar puncture […]
Read more »